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RIASSUNTO 
 
 
Il sistema linfatico consiste in una fitta rete di capillari e vasi che vanno a formare un 
circolo aperto e monodirezionale parallelo a quello sanguigno. Tra le sue più importanti 
funzioni figurano l’assorbimento degli acidi grassi ed il mantenimento dell’omeostasi 
tissutale mediante drenaggio di liquidi e proteine plasmatiche fuoriuscite dai capillari 
sanguigni nei tessuti. Il circolo linfatico, attraverso le stazioni linfonodali, svolge anche 
un ruolo determinante nel trasporto delle cellule immunitarie, garantendo la 
sorveglianza immunologica e permettendo alle cellule immunitarie di raggiungere 
velocemente il sito di danno. Lo studio della circolazione linfatica è sempre più 
importante in oncologia, visto il suo coinvolgimento nei meccanismi di migrazione 
delle cellule neoplastiche che portano allo sviluppo di metastasi.  
Lo studio dei vasi linfatici è stato per lungo tempo ostacolato dalla difficoltà nella loro 
identificazione e distinzione dai vasi sanguigni. La recente scoperta di marcatori come 
Podoplanina (PDPN), “lymphatic vessel endothelial hyaluronan receptor 1” (Lyve-1) e 
“Prospero- related homeobox 1”(Prox-1), che sono espressi specificamente in cellule 
endoteliali linfatiche, ha notevolmente favorito il loro studio istologico in tutti i distretti 
dell’organismo, compreso il cuore. Infatti, anche se la prima descrizione dei vasi 
linfatici nel cuore risale a circa tre secoli fa, solo di recente è stato rivalutato il loro 
ruolo sia nel mantenimento dell’omeostasi del tessuto interstiziale che in condizioni 
patologiche. Restano ancora da chiarire i meccanismi che regolano la linfangiogenesi a 
livello cardiaco ed i fattori di crescita coinvolti.  
Il più rilevante sistema di regolazione della linfangiogenesi si sviluppa sull’asse VEGF-
C/VEGFR-3, ma anche altri fattori di crescita si sono dimostrati capaci di stimolare la 
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crescita di vasi linfatici. Ad esempio il “Plateled derived growth factor” (PDGF) è un 
fattore di crescita da tempo conosciuto per la sua azione pro-angiogenica e il suo 
coinvolgimento nei meccanismi di reclutamento di cellule vascolari murali come i 
periciti. Recentemente è stata provata la sua importanza anche nell’induzione della 
linfangiogenesi tumorale. 
La prima fase di questo lavoro consiste nella caratterizzazione immunofenotipica, 
strutturale ed ultrastrutturale dei vasi linfatici in diversi organi umani e murini. Sezioni 
istologiche, ottenute sia da campioni autoptici umani che da organi isolati da modelli 
sperimentali, sono state analizzate tramite tecnica immunoistochimica in fluorescenza 
per verificare l’espressione dei più importanti markers linfatici. I markers risultati più 
specifici e maggiormente espressi sono quindi stati selezionati per valutare fenotipo, 
densità e distribuzione del sistema linfatico.  
La distribuzione dei vasi linfatici nel cuore umano e murino risulta simile. Questi si 
concentrano principalmente nelle regioni subepicardiche e negli spazi interstiziali che 
circondano arterie e vene. Un piccolo numero di capillari linfatici si ritrova nelle parti 
più profonde del muscolo cardiaco tra i cardiomiociti. 
La successiva analisi mediante microscopia elettronica ci ha permesso di analizzare le 
caratteristiche ultrastrutturali associate ai vasi linfatici, non facilmente rilevabili con 
altre metodiche. I vasi linfatici mostrano una parete molto sottile rispetto ai vasi 
sanguigni, una membrana basale assente o discontinua e frequenti interruzioni del 
monostrato endoteliale, conosciute come fenestrature. Un'ulteriore conferma della 
natura linfatica dei vasi analizzati è stata ottenuta tramite tecnica Immunogold con 
anticorpi specifici per il Lyve-1. 
Le tecniche precedentemente descritte ci hanno permesso di ottenere informazioni 
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esclusivamente bidimensionali, mentre l’architettura vascolare all’interno dell’organo è 
tridimensionale. Per superare questo limite tecnico è stato quindi messa a punto una 
nuova tecnica, denominata micro-linfangiografia in fluorescenza. In seguito 
all’iniezione di due traccianti fluorescenti, l’intero spessore del ventricolo di ratto viene 
analizzato al microscopio confocale. La tecnica permette di ottenere ricostruzioni 
tridimensionali della rete di vasi linfatici all’interno dell’organo. 
Nella fase successiva del lavoro sono stati valutati gli aspetti funzionali del 
sistema linfatico cardiaco. Il tessuto cardiaco è stato analizzato sia nelle condizioni 
normali, sia nelle condizioni conseguenti allo sviluppo di diverse cardiomiopatie. 
Ognuna delle cardiomiopatie analizzate è scatenata da un diverso agente eziologico.  
Nella cardiomiopatia ipertrofica ostruttiva (HOCM) è la mutazione di geni codificanti 
per proteine sarcomeriche a determinare lo sviluppo di ipertrofia settale accompagnata 
da disfunzione diastolica. Il danno ischemico è invece la causa scatenante della più 
comune cardiomiopatia di origine estrinseca, ovvero l’infarto del miocardio (MI). La 
cardiotossicità risulta infine tra i principali effetti avversi conseguenti al trattamento con 
diversi farmaci antitumorali come Doxorubicina e Imatinib . Il primo farmaco fa parte 
della famiglia delle antracicline, e come tale determina un effetto cardiotossico 
ampiamenente studiato e conosciuto. L’Imatinib è invece un inibitore dei recettori 
tirosina-chinasici (TKI) e rappresenta uno dei più grandi successi della medicina per 
quel che riguarda la cura delle neoplasie, approvato per il trattamento della leucemia 
mieloide cronica e dei tumori gastrointestinali. Tra i principali target dell’IM figurano 
recettori di grande importanza per la regolazione dell’angiogenesi nonché della 
linfangiogenesi, come il c-kit, il PDGFR e il VEGFR-3. 
Lo studio di campioni derivanti da miectomie chirurgiche di pazienti affetti da HCM ha 
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messo in evidenza una forte risposta linfangiogenica all’interno dell’organo. I risultati 
dell’analisi immunoistochimica indicano una sensibile riduzione del numero di capillari 
sanguigni, in termini di densità (numero di vasi per unità di area analizzata). Questa 
alterazione del letto vascolare sanguigno risulta semplice da giustificare se si tiene conto 
di quelle che sono le principali caratteristiche istomorfologiche della malattia, ovvero la 
fibrosi interstiziale, l’aumento della dimensione dei miociti ed il loro disarray. Il 
comportamento del sistema linfatico ha però un andamento completamente diverso. Si 
osserva un aumento marcato della densità dei vasi linfatici sia a livello dello spesso 
strato di tessuto fibrotico presente nel versante subendocardico, sia a livello dei tessuti 
muscolari cardiaci più profondi. L’aumento in termini di densità è accompagnato da un 
altrettanto marcato incremento dell’indice proliferativo che è stato misurato andando a 
quantificare i livelli di espressione nucleare di proteine specifiche del ciclo cellulare e 
della mitosi. 
Nella risposta dell’organo ad un insulto ischemico come l’infarto, è stato osservato un 
significativo aumento del numero dei vasi linfatici. Questo aumento risulta differito 
rispetto alla risposta angiogenica e funzionalmente associato alle diverse fasi di 
maturazione della cicatrice fibrotica.  
Anche nella cardiotossicità indotta da DOXO si registra un aumento di densità della 
componente linfatica associata alla marcata deposizione di collagene tipica di questa 
cardiopatia.  
Un comportamento completamente diverso si osserva invece nella cardiotossicità 
indotta da IM. Il cuore degli animali trattati con il farmaco mostra, in associazione ad 
una forte riduzione dei vasi linfatici, un aumento nel contenuto relativo di acqua. Il 
trattamento con il farmaco è quindi in grado di alterare la funzione di drenaggio del 
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miocardio contribuendo allo sviluppo della disfunzione dell’organo. A livello 
ultrastrutturale, abbiamo inoltre potuto documentare in microscopia elettronica 
un’estesa compromissione dei mitocondri nei vasi sanguigni e linfatici. 
In conclusione i dati ottenuti dimostrano che, in ognuna delle condizioni 
patologiche analizzate, il sistema linfatico risulta importante nella risposta del cuore ai 
diversi insulti subiti ed assume un ruolo determinante per il suo rimodellamento. 
L’interferenza nei meccanismi linfangiogenici può determinare un’alterazione 
dell’omeostasi tissutale e quindi contribuire negativamente allo sviluppo di cardiopatie 
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THE LYMPHATIC VASCULATURE 
 
 The lymphatic system comprises a one way, open-ended complex network of 
capillaries, precollecting and collecting trunks, ducts and lymph nodes. It is involved in 
transport of tissue fluids, extravasated plasma proteins and cells back into the blood 
circulation. Lymph is formed when interstitial fluids enter the terminal lymphatic 
capillaries that drain the lymph to larger contractile lymphatics, which possess valves as 
well as a smooth muscle wall and are called the collecting lymphatics
1
. As the 
collecting lymph vessel accumulates lymph from more and more capillaries in its 
course, it becomes larger and represents the afferent lymph vessel as it enters a lymph 
node. Here the lymph percolates through the lymph node tissue and is removed by the 
efferent lymph vessel. An efferent lymph vessel may directly drain into one of the large 
lymph ducts (right or thoracic), or may empty into another lymph node as its afferent 
lymph vessel
2
. Both lymph ducts return the lymph to the blood stream by emptying into 
the subclavian veins
3
. 
In spite of these connections and the close juxtaposition of lymphatic vessels 
with vein and arteries, this system is anatomically and entirely separated from the blood 
circulatory system. Anatomically, lymphatic vessels differ from blood ones in several 
ways. The lymphatic capillaries are made up of a single-cell layer of endothelial cells 
that form a thin-walled, fenestrated and blinded vessel lacking pericytes and a 
continuous basal lamina.  
The presence of specific junctional proteins between endothelial cells of initial 
lymphatics has been recently described. The endothelium of initial lymphatics contains 
vascular endothelial cadherin (VE-cadherin) and platelet endothelial cell adhesion 
molecule-1 (PECAM-1). These proteins are typical of both adherens junctions and tight 
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junctions and are partially colocalized at the borders of oak leaf-shaped endothelial cells 
to form discontinuous, button-like junctions (buttons) structurally different from the 
zipper-like junctions (zippers). Regions between buttons in initial lymphatics are 
openings where fluid can enter without repetitive formation and dissolution of 
intercellular junctions
4
. 
Lymphatic capillaries also possess anchoring filaments, specialized extracellular 
fibrillar structures linking lymphatic endothelial cells (LECs) to the extracellular matrix, 
which also help to maintain the patency of the vessels in conditions of high interstitial 
pressure or inflammatory state, facilitating the uptake of fluid, macromolecules and 
cells
5,6,7
. The lymphatic system, unlike the blood lacks a central pump. The force 
driving the lymph is generated by the contraction of smooth muscle cells laying on the 
collecting vessels, by respiratory movements and by squeezing of skeletal muscle 
contraction
8
. Lymphatic pre-collecting and collecting trunks have a different structure 
than lymphatic capillaries: in addition to their large diameter they are surrounded by a 
muscular wall and by the presence of internal valves prevent the retrograde flow of 
lymph fluid. 
The main role of the lymphatic vascular system is the maintenance of tissue fluid 
pressure homeostasis by draining excess interstitial fluid leaking from blood capillaries. 
Furthermore, the lymphatic system plays a central role in the immune reactions 
allowing the circulation of immune cells to and from the lymph nodes. Lymphatic 
system for example is the migration way of antigen-presenting cells (APCs), such as 
dendritic cells, from tissues to lymph nodes in immune surveillance. Recently 
ymphatics have gained relevance in oncology because they are also routes for spreading 
cancer cells 
9,10,11
. The lymphatic system may be also implicated in drainage and 
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clearance of toxic substances from tissues. Finally, the lymphatic vessels in the intestine 
is involved in the dietary fat (lipids and fat-soluble vitamins A, E, D and K) absorption 
and subsequent transport to the circulatory system.  
Although the function and structure of lymphatic vessels are partially defined, its 
embryonic development is still partially known. Two alternative mechanisms have been 
proposed to explain the origin of the lymphatic system. The most widely accepted view 
was proposed by Florence Sabin in the 1902, indicating that lymphatic vessels originate 
from a primitive lymph sacs generated by endothelial cells, which sprout from the 
cardinal vein during the early stages of development. Lymphatic vessels grow out 
“centrifugally” from these sacs12. In contrast, an alternative model proposes an 
autonomous origin of the lymphatic system from mesenchymal precursor cells. By this 
hypothesis, lymphatic vessels evolve independently from the embryonic vein and the 
connections between two vascular systems are established during a later phase of 
development
13
.  
The investigation of lymphatic vessels has been long hampered by the difficulty 
in their identification and distinction from blood vessels, particularly from venules. 
Moreover, when lymphatics are not filled with lymph, they tend to collapse and may 
become impossible to recognize. The recent discovery of several lymphatic endothelial 
cell-specific markers that consistently and specifically reacts with lymphatic 
endothelium, has made histological study of lymphatic vessels feasible. The first marker 
expressed in the initial stage of lymphatic development is “lymphatic vessel endothelial 
hyaluronan receptor 1”(Lyve-1)14. This marker is an integral membrane glycoprotein, 
homolog of the hyaluronan receptor CD44
15
. Lyve-1 is expressed in a subpopulation of 
endothelial cells localized in the cardinal vein in the early stage of lymphatic 
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development. In adults, the expression of Lyve-1 is extended to liver sinusoids, some 
lung blood vessels, high endothelial venules and active tissue macrophages
16
. However, 
Lyve-1 does not seem to be essential for the lymphatic system since transgenic mice 
lacking this protein exhibit a normal development of lymphatic vessels and immune cell 
trafficking
17
. 
Among the complex network regulated by Vascular Endothelial Growth Factors 
(VEGFs), the receptor 3 (VEGFR-3), is specific for lymphangiogenic factors VEGF-C 
and VEGF-D
18,19
. During the early stage of development, this receptor is highly 
expressed in the blood vascular endothelial cells, but after mid-gestation it is expressed 
only by lymphatic endothelial cells. Genetic manipulation of VEGFR-3 affects 
lymphatic development. All VEGFR-3 knock-out mice die in utero of cardiac failure 
before lymphatic vessels formation
20,21
. The expression of this receptor is a key element 
involved in the establishment of LECs identity and is tightly related to another 
important lymphatic marker: the “Prospero- related homeobox 1”(Prox-1). Prox-1 is a 
transcription factor strictly required for the specification of LECs since it is expressed 
during all stage of development only in lymphatic vessels
22,23
. Prox1 is initially 
expressed by a subpopulation of cells in the cardinal vein
24
. Its activation induces the 
expression of LECs-specific genes like Podoplanin and VEGFR-3 and downregulates 
genes involved in blood endothelial cells (BECs) specification
25
. Lyve-1
pos
/Prox-1
pos
 
cells are able to bud off from cardinal vein in a polarized manner. Subsequently, these 
budding LEC progenitors proliferate and migrate to form the embryonic lymph sac and 
lymphatic vascular network. Total or partial inactivation of Prox1 result in a lymphatic 
hypoplasia and a general failure in LECs differentiation with a complete lack of 
lymphatic vasculature in the absence of defects of the blood stream
22
. Moreover, the 
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temporal inactivation of Prox1 alters the phenotypic commitment into mature LECs and 
reverts them to BECs identity
26
. These data prove the importance of prox-1 expression 
for LECs specification and maintenance, not only during the embryonic development 
but also in the adult life. After the formation of lymph sacs, the Lyve-1
pos
/Prox-1
pos
 cells 
begin to form a capillary network.  
In this stage cells express another marker, the mucin-type transmenbrane 
glycoprotein, Podoplanin (Pdpn). Pdpn null mice die at birth due to respiratory failure 
and have defects in lymphatic but not in blood vessel pattern formation. These defects 
are associated with diminished lymph transport, congenital lymphoedema and dilation 
of lymphatic vessels
27,28
. Pdpn may contribute to LECs adhesion and migration, and 
may induce proper connections between superficial and deep lymphatic plexuses. 
 
Tab 1: Markers of lymphatic (LEC) and blood vascular endothelial (BEC) cells  
Marker Molecular function LEC BEC References 
PROX-1 Transcription factor ++ - 21 
Pdpn 
Transmembrane 
glycoprotein 
++ - 24 
CD31 Adhesion molecule + ++ Albeda
29
 
CD34 Adhesion molecule - (+)
a 
++ Young
30
 
CD44 Hyaluronan receptor - + Kriehuber
31
 
LYVE-1 Hyaluronan receptor ++ - 12, 13 
VEGFR-
3 
Tyrosine kinase 
receptor 
++ - (+)
b 
17 
 
a 
 CD34 expression has been also detected on LECs  
b
 VEGFR-3 expression has been observed in tumor-associated blood vessels
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THE CARDIAC LYMPHATIC SYSTEM
 
Although the description of the presence of lymphatics in the heart has been 
reported over three century ago, their role and function in normal and pathologic states 
are still largely unclear due to the intrinsic technical difficulty to study the cardiac 
lymph flow and lymphatic vessels. The recent identification of lymphatic endothelial 
cell-specific markers, the generation of new animal models and lymphatic vascular 
imaging technology led to a reevaluation of the importance of cardiac lymphatic 
vasculature in the control of heart function. The principal role of the cardiac lymphatic 
system appears to be restricted to the maintenance of tissue fluid homeostasis, although 
an active role also in immune responses to inflammatory state and in cardiac failure has 
recently emerged. A series of observations allowed to correlate the interruption of the 
lymphatic flow with significant anatomic and functional changes of the heart
32,33
. The 
first technique to identify cardiac lymphatics utilized the injection of a dye
34
. Initial 
studies based on this technique were able to identify and describe the lymphatic system 
organization in the heart. Cardiac lymphatic vessels have been found in several aspects 
of the cardiac wall including the subepicardium, mid-myocardium and 
subendocardium
35,36
. The principal limitation of this technique is that only “non 
contracting” lymphatic vessels are detectable whereas collapsed vessels cannot be filled 
by the dye
37
. 
In the mammalian heart, two forms of cardiac lymphatic vasculature have been 
described: the lymphatic capillary plexus and the collecting lymphatic vessels. The 
lymphatic capillary plexus is present in the mid-myocardium and subendocardium 
where it lies parallel to the endocardial surface. The collecting lymphatic vessels can be 
seen in the subepicardium where they join into single or multiple collecting trunks. 
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These structures proceed toward mediastinal lymphatic vessels and then merge into 
subclavian vein, completing the lymph flow circuit. The cardiac lymph flow is 
controlled by active and passive lymphatic pumping. The active part is generated by 
spontaneous contraction of muscle cells of the collecting vessel wall but has a limited 
capacity to drain large quantity of fluid. In contrast, other forces related to cardiac 
muscle contraction that probably represents the major way of draining lymph fluid drive 
passive lymphatic flow
38,39
. 
A series of recent promising research studies have underlined the beneficial 
effect of active lymph drainage on heart function, especially in cardiac pathologies. 
Analyzing autoptic tissues of the human heart, Ishikawa et al. have tried to elucidate the 
role of the lymphatic system in the entire process of tissue repair and scar formation 
after myocardial infarction (MI)
40
. According to this study, lymphangiogenesis takes 
place after blood vessel angiogenesis and may be involved mainly in the maturation of 
fibrotic tissue and in the definition of scar formation through the drainage of excessive 
proteins and fluids. Specifically, lymphatic vessels are absent in the early stages of scar 
formation, in which blood capillaries prevail to decrease thereafter with the progression 
of the infarct. In parallel, lymphatic vessels begin to appear in the peripheral area near 
the infarct. Subsequently, they appear as dilated structures in the peripheral area and 
with capillary features in the central area of granulation tissue. Later in the completion 
of myocardial infarction, lymphatic density increases during the final stage of scar 
formation. These results demonstrate that active drainage of fluids and removal of the 
end products of cellular damage by lymphatics play an important role in the 
determination of tissue response to an acute ischemic insult. 
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PDGFR SIGNALING AND LYMPHANGIOGENESIS 
PDGFRs are surface tyrosine kinase receptors for members of the platelet-
derived growth factor (PDGF) family. These receptors are involved in many biological 
functions such as cell proliferation, differentiation, growth and tissue development. 
Autocrine activation of PDGFR signaling pathway is also implicated in a variety of  
diseases including cancer
41
. There are two forms of the PDGF-R, alpha and beta, each 
encoded by a different gene
42
.  This receptor is expressed by perivascular mesenchymal 
cells, likely representing vascular mural cell progenitors (vSMC and pericytes). In 
particular, PDGFR beta () is strongly expressed in tip cells of the angiogenic sprouts 
and in the endotelium of growing arteries at sites where pericytes are actively recruited 
and vSMC population is expanding
43,44
.  
It should be emphasized that PDGF-B and PDGFR- knock-out mice exhibit 
hemorrhagic and edematous phenotypes in early embryos due to defective development 
and recruitment of vascular mural cells (pericytes and SMC) onto blood vessels. PDGF 
receptors have been localized on blood vessel endothelial cells, suggesting a direct role 
of PDGFs on angiogenesis
45
. However, recent studies suggest that members of the 
PDGF family including PDGF-AA, -AB and -BB are able to induce lymphatic vessel 
growth in the mouse cornea
46
. The mechanism of this PDGF induced 
lymphangiogenesis is not still clear, although an indirect participation of the VEGF-C/-
D/VEGFR-3 signaling pathway has been proposed. Thus, PDGF combined with their 
receptors constitute a very important system regulating both angiogenesis and 
lymphangiogenesis. 
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HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY 
Hypertrophic cardiomyophathy (HCM) is a primary cardiac disorder characterized by 
asymmetrical hypertrophy of the left ventricle in the absence of conditions that could 
lead to an hemodynamic overload (aortic stenosis, hypertension, thyroid disease).
47
  
Since its initial description in 1958, this pathology has generated intense 
investigation.
48,49,50,51,52 
HCM is a congenital cardiac disorder inherited as an autosomal 
dominant trait and its genetic basis are well defined. Most of the genes involved, encode 
for proteins linked to the contractile unit of the cardiomyocyte.
53,54,55,56,57
 
The complexity of this disorder is remarkable by a heterogeneous clinical presentations, 
ranging from no symptoms to severe heart failure and sudden cardiac death.
58
  
To date, the molecular steps linking the genetic mutation to the clinical phenotype 
remain still undiscovered. 
About 30-50% of individuals with HCM demonstrate an obstruction to the left 
ventricular outflow caused by asymmetric septal hypertrophy. 
The obstructive variant of HCM, Hypertrophic obstructive cardiomyopathy (HOCM) is 
also historically known as idiopathic hypertrophic subaortic stenosis (IHSS) and 
asymmetric septal hypertrophy (ASH).  
Surgical septal myectomy is reserved for those patients who, despite drug 
therapy, still show severe symptoms with a marked obstruction of the septum and an 
unacceptable lifestyle.
59
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ANTICANCER DRUG CARDIOTOXICITY 
Several chemotherapeutic drugs have been implicated in cardiotoxicity. In 
particular, anthracyclines have been clearly identified as a cardiotoxic agent, however 
also Tyrosine Kinase Inhibitors (TKIs)
60
 have been shown to induce cardiovascular 
events. 
Anthracyclines are one of the most active anti-neoplastic drugs against 
hematologic
61
 and solid
62
 tumors, however, their cardiotoxic adverse effects such as 
cardiomyopathy and symptomatic Congestive Heart Failure (CHF) have limited their 
clinical use. Doxorubicin (DOXO) is a member of anthracyclines family. The 
mechanism of action of DOXO is complex and still somewhat unclear, although is 
known that DOXO interact with DNA by intercalation and inhibition of macromolecular 
biosyntesis. In particular, DOXO stabilizes topoisomerase II complex after its breaking 
action on the DNA chain for replication. This event prevents the DNA double helix 
from being resealed and thereby stopping the process of replication. Like other 
chemotherapeutic agents, DOXO do not possess a specific activity on cancer cells, but 
also affects normal cells, leading to severe side effect. Moreover, anthracyclines are 
known for causing cardiotoxicity that most often manifests many years after treatment. 
Cardiotoxicity may be due to different deleterious events in cardiac muscle cells, which 
include interference with the ryanodine receptors of the sarcoplasmic reticulum, free 
radical formation or severe metabolic dearrangement. 
TKIs represent a decisive turning point in the modern medicine, since they 
specifically interfere with the proliferation/apoptosis pathways of neoplastic cells, and 
their introduction gained a formidable increase in survival rates of patients affected by 
specific cancer. Tyrosine kinases play a critical role in the modulation of growth factor 
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signaling. Activated forms of these enzymes can cause increases in tumor cell 
proliferation and growth, induce anti-apoptotic effects, and promote angiogenesis and 
metastasis. Because all these effects are initiated by receptor tyrosine kinase activation 
(also caused by somatic mutation), these enzymes are key targets for inhibitors. TKIs 
are examples of the recent trend toward targeting multiple receptor kinases, such as 
Vascular Endothelial Growth Factor (VEGF) receptor 1–3, Platelets Derived Growth 
Factor (PDGF) receptor α/β, KIT, FMS-related tyrosine kinase 3 (FLT3), colony-
stimulating factor 1 receptor (CSF1R) and rearranged during transfection (RET) 
receptor tyrosine kinases.
63
 Although this class of drugs directly aims oncogenic 
pathways, the clinical use of TKIs resulted in alteration of cardiac function. Although 
TKIs toxic effect seems to be manageable and reversible at a short- or mid- term follow-
up, the development of late cardiovascular sequelae is more than a speculative 
possibility. Unfortunately, differences between pediatric, adult, and elderly patients and 
the lack of uniform modality in detecting and reporting cardiac events makes adequate 
estimates even more difficult
64,65
. Thus, it seems to be necessary to deepen our 
understanding on the mechanisms of cardiotoxicity, whose explanation have been so far 
ambiguous.  
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AIM 
The aim of our study was to characterize the cardiac lymphatic system and to 
evaluate its role in four different pathological conditions .  
To obtain background information, our ability to detect lymphatic vessels was 
extensively challenged by studying human and animal tissues with immunofluorescence 
and confocal microscopy. Moreover, fluorescence micro-lymphangiography on whole 
mount preparations of the heart and skin from rats were employed to define by confocal 
microscopy the lymphatic architecture and 3D reconstruction. Additional studies were 
performed to characterize ultrastructural aspects of lymphatics by Transmission 
Electron Microscopy (TEM) implemented by immunogold labelling.  
The first pathological study was performed in a mouse model of myocardial 
infarction (MI), to ascertain the role of lymphangiogenesis in the entire process of 
myocardial repair and scar formation.  
Then we tested lymphatics behavior in hypertrophic obstructive cardiomyopathy 
(HOCM), a genetically defined cardiomyopathy also resulting, through different 
mechanisms, in collagen deposition and fibrotic scarring. 
Subsequently,  we focused our attention on Imatinib Mesylate (IM) (Gleevec©, 
Novartis, Basel, Switzerland) a small-molecule TKIs, whose introduction revolutionized 
the treatment and the survival rate of Chronic Myeloid Leukemia (CML) and other 
types of tumors
66,67
. Our interest has been specifically addressed to IM because it 
possesses a potent activity against c-KIT and PDGFR, tyrosine kinase receptors 
involved in lymphangiogenesis and closely related to the phenotype of Cardiac 
Progenitor Cells (CPCs). In a rat model of IM induced cardiomyopathy we attempted to 
demonstrate that impairment of lymphangiogenesis may affect cardiac structure and 
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function.  
Finally, to assess whether inhibition of lymphatics was a specific effect of TKI 
or a common mechanism implicated in cardiotoxicity, the analysis of lymphatic 
structures was conducted in a model of DOXO induced cardiomyopathy. 
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Human tissue samples  
 Normal human myocardial and skin samples were collected from archive 
material of autopsies performed by the Department of Pathology, University of Parma. 
Only cases devoid of cardiovascular or cutaneous diseases were included in this study. 
Tissue specimens obtained within 24-48 hours after death, were embedded in paraffin 
and 5 m histological sections were obtained for the immunohistochemical analysis of 
lymphatic vessels. 
Lung tissue was collected from patients affected by lung cancer and undergoing 
lung resections, enrolled after informed consent to the employment of biologic samples 
for research purpose. Transported under sterile condition to the Department of 
Pathologic Anatomy, samples were dissected under hood at laminar flow.  
Portions of healthy lung tissue were sampled by the medical staff ensuring the priority 
of their use for diagnostic purposes. The correct sampling procedure was confirmed by 
the subsequent histologic analysis. 
Left ventricular myocardial fragments were obtained from 31 patients affected 
by HOCM undergoing septal myotomy-myectomy.  
Hypertrophic heart specimens were obtained from patients with aortic stenosis 
(AoS) undergoing valve replacement for rheumatic disease or degenerative 
calcification. Myectomies collected were the waste material of outflow tract releasing 
surgical interventions.  
All collected samples were formalin fixed and paraffin embedded for 
morphometric analysis and immunohistochemistry.  
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Experimental models 
 The study population consisted of male Wistar rats (Rattus norvegicus, IM 
model), Female Fischer 344 rats (DOXO model) and male CD1 mice (MI model) breed 
in our departmental animal facility. Animals were kept in unisexual groups of four 
individuals from weaning (4wk after birth) until the onset of the experiments, in a 
temperature-controlled room at 22–24 °C, with the light on between 7.00 AM and 7.00 
PM. The bedding of the cages consisted of wood shavings, and food and water were 
freely available. The investigation was approved by the Veterinary Animal Care and 
Use Committee of the University of Parma and conformed with the National Ethical 
Guidelines (Italian Ministry of Health; D.L.vo 116, January 27, 1992) and the Guide for 
the Care and Use of Laboratory Animals (NIH publication no. 85–23, revised 1996). 
 
Animal model of myocardial infarction (MI) 
 MI was induced in male CD1 mice weighing 35-40g (Charles River, Comerio, 
Italia) by permanent ligation of left anterior descending artery using a 6 to 0 silk suture. 
Sham-operated animals underwent a similar procedure without ligation.  
 Each animal was anaesthetized with a solution of Xilazine (2.5mg/Kg) and 
Ketamine (50mg/Kg.) and the surgery was performed with mechanical ventilation. 
(volume: 8-9 mL/g; frequency: 165/min). After autonomous respiratory recovery, 
animals were placed in the cage alone. Mortality observed after surgery was less than 
10%. 
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Animal model of Doxorubicin induced cardiomyopathy 
 Female Fischer 344 rats (n=160) at 3 months of age (body weight 180±10 g) 
received DOXO in six equal intraperitoneal injections of 2.5 mg/kg b.w over a period of 
2 weeks to reach a cumulative dose of 15 mg/kg b.w. .Control rats (CTRL) were 
injected with the vehicle alone (lactose, 75 mg/kg in saline) in the same regimen as 
DOXO. Animals were sacrificed at 3 weeks after the first injection. 
DOXO solution was obtained by dissolution of powder (Pharmacia-Upjohn, Milan, 
Italy) in vehicle solution (1% lactose in sterile saline) at a concentration of 0.15 mg/ ml.  
 
Animal model of IM induced cardiomyopathy 
 Thirty four 8 wk old rats, weighing 200 - 250 g were divided into three groups. 
(1) IM50 (n=8), animals subjected to intra-peritoneal (i.p.) injections of 50mg/kg IM 
three times a week for three weeks; (2) IM100 (n=10), animals subjected to i.p. 
injections of 100mg/kg IM three times a week for three weeks; (3) CTRL (n=8), 
animals injected with equal volume of saline and taken as control. Rats were 
anesthetized with droperidol + fentanyl citrate (Leptofen, Farmitalia-Carlo Erba, Milan, 
Italy; 1.5mg/kg im) which we have found to induce negligible changes in cardiovascular 
parameters when telemetrically recorded in conscious animals (unpublished data). 
Finally, hemodynamic data were invasively collected and the heart of each animal was 
perfusion fixed for morphometric and immunohistochemical studies. 
 IM 100 mg capsules were a gentle gift of the Department of Hemathology, 
representing discarded material from patient’s drug withdrawal. The capsules were 
dissolved with prolonged stirring in sterile water previously adjusted at ph=2 with 10N 
HCl and then, before the injection, re-adjusted at pH=6,2 with sodium hydroxide 
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(NaOH) 10N. The suspension was finally filtered to obtain a sterile solution devoid of 
solid particles and stored in aliquots at -80 °C. At the time of administration the drug 
was diluted according to the desired concentration and to a volume of injection ranging 
from a minimum of 0.7 to a maximum of 1.2 ml.  
 
Anatomical parameters  
 The hearts of anesthetized animals were arrested in diastole by injection of 5 ml 
cadmium chloride solution (100 mmol, iv) and the myocardial vasculature shortly 
perfused at a physiological pressure with a heparinized PBS-solution, followed by 
perfusion with 10% formalin solution. The heart was then excised and placed in 
formalin solution (10%) for 24 hours. 
 Then, the right ventricle (RV) and the left ventricle (LV) inclusive of the septum 
were separated. Subsequently, the heart was sliced in three 1-mm thick transversal 
sections, at the basal, equatorial and apical levels of the ventricle. Afterwards, the 
sections were embedded in paraffin. Five-μm thick slices were finally cut from the 
equatorial portion of the LV free wall for morphometric and immunohistochemical 
studies. 
 
Theoretical water content 
 Hearts harvested from IM treated and control rats were cleaned from other 
tissues, major vessels and from excess water and blood. Subsequently, the entire atria 
and fragments of the septum, left and right ventricles were separately weighed. 
Thereafter, tissues were weighed after dehydration, achieved by several microwave 
heating cycles until non changes in weight of each individual tissue fragment was 
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measured. The wet weight to dry weight ratio was then computed and theoretical water 
content was obtained. 
 
Immunohistochemical analysis 
 Five-micrometer-thick sections obtained both from human samples and from 
each group of animals were analyzed under fluorescence microscopy to determine the 
effects induced by the different cardiopathies on lymphatic and blood vessel density. 
Sections were incubated with lymphatic specific primary antibodies: polyclonal rabbit 
to LYVE1, (cod.ab14917, Abcam, Cambridge UK) Polyclonal rabbit to Prox1 (cod 
DP6501PX, Acris Herford Germany); monoclonal mouse to D2-40, (cod CM266, 
Biocare, Concord USA). For the identification of blood vessels, monoclonal mouse 
anti--smooth muscle actin antibody, (cod a5228, Sigma St. Louis, MO) and polyclonal 
rabbit anti-von Willebrand factor (vWF, cod F3520, Sigma St. Louis, MO ) were used. 
Myocytes were identified by staining the same sections with monoclonal mouse anti--
sarcomeric actin antibody (anti--SARC; cod.a2172, Sigma St. Louis, MO). Mitotic 
cells were recognized by the nuclear expression of the phosphorylated form of histone 
H3 (Ph-H3, cod.06-755, Millipore Corporation, Billerica, MA, USA, ). 
Tissue sections were incubated, respectively, with the primary antibodies followed by 
conjugated specific secondary antibodies.  
FITC, TRITC-, Cy5- conjugated anti-mouse, anti-rabbit secondary antibodies (Jackson 
Laboratory, Baltimore, PA, USA) were used to detect simultaneously the different 
epitopes. Nuclei were recognized by DAPI (4’,6-diamidine-2-phenyndole, Sigma St. 
Louis, MO) staining. 
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Ultrastructural and immunoelectron microscopic (ImmunoGold) detection of 
lymphatic vessels 
 Hearts harvested from normal and IM treated rats were analyzed by transmission 
electron microscopy (TEM) to detect structural and subcellular alterations involving 
lymphatic vasculature.  
 For ultrastructural analysis, the specimens of interest were fixed in 2.5% 
gluteraldehyde for 6 h. The tissues were then postfixed in 1% osmium tetroxide (OsO4) 
and dehydrated by increasing concentrations of alcohol. Following this procedure, 
samples were washed with propylene oxide and embedded in epoxy resin embedding 
media. Sections of 0.5 m thickness were stained with methylene blue and safranin to 
select morphologically the field of interest. Subsequently, ultrathin sections were 
collected on a 300-mesh copper grid and, after staining with uranyl acetate and lead 
citrate, were qualitatively examined under a transmission electron microscope (Philips 
EM 208S). 
 For ImmunoGold detection the grids were incubated for 10 min in sodium 
periodate, a saturated solution necessary for the etching. After a series of washing the 
grids were incubated with Na-borohydride for 5 min and TBS pH 8 for 10 min; 
afterward sections were saturated with BSA 2% for 30 min an then incubated at 4°C 
overnight with the primary antibody polyclonal rabbit anti-LYVE1, (cod.ab14917, 
Abcam Cambridge, UK). Grids were rinsed for 3 × 5 min in TBS (ph 8) and BSA for 10 
min and then incubated for 1 hr with goat anti-rabbit IgG conjugated with 10 nm gold 
particles (EMGAR10, BBI, United Kingdom) diluted 1:10 in TBS (pH 8.2). After 
rinsing for 2 × 5 min in TBS (pH 8.2) and distilled water (dH20), grids were contrasted 
with 4% uranyl acetate in 50% ethanol and lead citrate, for 20 and 10 min, respectively. 
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Negative controls consisted of samples in which the immunoreaction was performed in 
with the use of an indifferent primary antibody. Although the immunogold methodology 
has been utilized by our Pathology laboratory since at least 2 decades, its specificty was 
tested in our preparations by using an antibody highly expressed in the myocardium 
such as a-smooth muscle actin followed by goat anti-mouse IgG conjugated with 10 nm 
gold particles. 
 
Fluorescence micro-lymphangiography 
 Lymphatic and blood vessel microvascular tridimensional architecture was 
studied by double-label whole-mount confocal microscopy. 
Wistar Rats were anesthetized with droperidol + fentanyl citrate (Leptofen, Farmitalia-
Carlo Erba, Milan, Italy; 1.5mg/kg im), and the jugular vein was catheterized by a PE50 
polypropilen cannula. One ml of the fluorescent vascular tracer BSA-FITC (66 kDa; 30 
mg/ rat, Sigma, St. Louis, MO) was injected intravenously. Rats were sacrificed 2 hours 
later, 3 minutes after 1 ml intravenous injection of a second fluorescent dye, Dextran-
TRITC (160 kDa; 15 mg/rat, Sigma, St. Louis, MO ), which served as a blood marker. 
Time interval from first injection to sacrifice is enough to allow BSA-FITC leakage 
from vascular bed to interstitium and then to lymphatic vessels. Delayed injection of the 
second tracer otherwise impede the same route confining Dextran-TRITC into blood 
vessels. Thus, blood vessels are labeled with both dyes, whereas draining lymphatics are 
labeled only by the green fluorescence of FITC. 
 Samples of the skin and heart were removed and fixed overnight in 4% 
paraformaldehyde. To decrease light scattering during imaging, tissues were optically 
cleared as described below. Briefly, specimens were processed in 20-ml plastic vials 
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and using a tissue rotator. The tissue was first washed extensively in PBS to remove 
paraformaldehyde. Specimens were then dehydrated with successive 15-min washes 
through a graded methanol (MeOH) series (25%, 50%, 75%, 95% and 100% v/v in 
distilled water). Tissue was cleared using Murray's clear (BABB), a solution of 1 part 
benzyl alcohol to 2 benzyl benzoate (v/v) (both from Sigma-Aldrich, St. Louis, MO). 
Specimens were run through a series of 3:1, 1:1 and 1:3 (v/v) MeOH: BABB and left in 
100% BABB for one week, until the tissue was transparent.  
 Specimens were examined using the Axiovert 200M inverted microscope (Carl 
Zeiss, Jena, Germany), integrated with the confocal system LSM 510 Meta scan head. 
Cleared whole-mount tissues mounted into a special Plexiglas chamber, were examined 
under 10× and 20× air objectives lenses. Images were scanned in fluorescence modes. 
Serial optical sections were recorded beginning at the top surface of the specimen, and 
the resultant stacks were rendered in three dimensions using AxioVision© (Carl Zeiss 
Imaging Solutions) and Huygens© (Scientific Volume Imaging) software to examine 
the 3D nature of the vascular network. 
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CHARACTERIZATION OF LYMPHATIC VASCULATURE IN NORMAL HUMAN 
TISSUES 
Several normal fetal and adult human tissue samples were examined to evaluate 
the specific expression of lymphatic endothelial cell markers. Histological sections were 
collected from autopsies and analyzed by immunofluorescence. 
 
Fetal and Adult Lung 
In the fetal lung, Pdpn is not exclusively expressed by lymphatic vessels, but is 
also present in type I pneumocytes precursors. In agreement with this finding, terminal 
bronchiolar profiles resulted Pdpn positive (Fig 1A). We also observed that the number 
of lymphatic vessels change during lung development (data not shown). In the 
canalicular phase the tissue shows the highest amount of lymphatics to progressively 
decrease thereafter.  
In adult lung a large amount of pulmonary Pdpn positive lymphatic vessels are 
located in association with bronchovascular bundles. Their presence within the lobule, 
the deeper part of the lung parenchyma, has been debated for years, particularly in 
regard to the presence or absence of true alveolar lymphatics
68697071
. Our study give a 
clear answer to this discussion, indeed we found small lymphatics also in interalveolar 
areas (Fig 1B). In addition, the connective tissue of the visceral pleura seem particularly 
rich in lymphatics. Quantitative overall estimation of the tissue indicates an average 
lymphatic density of 2,75 ± 1,1/mm
2
. 
In all lung developmental stages, from fetal to adulthood, lymphatic vessels are 
well distinguishable from blood vasculature, because the expression of Pdpn is not 
accompanied by the blood endothelial cell marker vWF (Fig 1A,B). 
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Fetal and Adult Heart 
IHC analysis of fetal human hearts demonstrated that Pdpn is exclusively 
expressed by lymphatics and Pdpn negative blood vessels are positive for vWF. 
Lymphatic vessels are mainly located in the perivascular interstitium adjacent to 
coronary artery and veins of the subepicardium. The typical perivascular distribution of 
lymphatics in the apical region of a normal fetal heart is shown in Figure 2. Lymphatics 
also show different morphologic features respect to blood vessels: the wall is thinner, 
the lumen is irregular and at time collapsed.  
A similar pattern of expression of lymphatics and blood vessel markers is 
present in the adult heart (Fig 3). Interestingly, it appears that in the heart fluid drainage 
mainly occurs in the pericardial region, which exhibits high density of large size 
lymphatic vessels. 
 
Adult Skin 
 Lymphatic vessels are also extensively present in the skin and are known to 
participate in a variety of physiological and pathological processes such as wound 
healing, inflammatory reaction, lymphoedema and scleroderma
727374
. Most of the 
lymphatic vessels have a patent lumen delineated by a tortuous and irregular profile. 
Some lymphatic vessels are completely or partially collapsed.  
 IHC analysis shows that human lymphatic vessels are consistently and intensely 
stained by Pdpn. Low intensity cross-reactivity was only found in some epithelial cells 
particularly in the basal layer of sebaceous glands. At variance with blood vessels, the 
endothelium and the subendothelial layer is negative for the vascular endothelial marker 
vWF. Blood vessels never show reactivity to Pdpn (Fig 4 A,B). Importantly, the specific 
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transcription factor for lymphatic commitment, Prox-1, is expressed in all endothelial 
cell nuclei lining lymphatic vessels (Fig 4 C,D).  
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CHARACTERIZATION OF LYMPHATIC VASCULATURE IN THE NORMAL 
RAT HEART 
 
Immunohistochemistry 
In agreement with previous observations made on the human heart, in the normal 
rat heart, lymphatic vessels are predominantly located in the subepicardium and in 
interstitial spaces surrounding arteries and veins (fig 5A,D,E). A small amount of thin 
lymphatic capillaries can be less frequently found between cardiomyocytes (Fig 5B). 
The quantitative estimation indicates that average lymphatic density is 2,66 ± 0.18 
/mm
2
, however the highest incidence of lymphatics was measured in the 
epimyocardium, where the density reaches values of 6,88 ± 0.53 /mm
2
. Moreover, 
lymphatic vessels located in the latter region exhibit a larger luminal area compared 
with that found in vessels of the endo-and mid-myocardium. We did not observed 
lymphatic collectors surrounded by muscular layer in any of the hearts analysed in the 
present investigation (Fig 5D,E). The IHC analysis indicates that endothelial cells of 
lymphatics present in the normal rat heart express all the lymphatic markers LYVE-1, 
Pdpn and PROX-1 and none of them express the blood endothelial marker vWF (Fig 
5A-E). 
 
Ultrastructural and ImmunoGold detection of lymphatic vessels by TEM 
TEM analysis of the normal rat heart allowed us to identify lymphatic vessels 
and to evaluate their specific ultrastructural features. Lymphatic vessels are often found 
in proximity of blood vessels and at time between cardiomyocytes (Fig 6A). The 
lymphatic wall is thinner with respect to blood vessels and capillaries. Basal lamina is 
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absent or at best discontinuous. In addition, interruption of the endothelial cell layer, 
due to the presence of fenestrations, is clearly documented (Fig 6 B).  
ImmunoGold detection of LYVE1 expression revealed a specific presence of this 
protein in the cytoplasm and its extensions of lymphatics (Fig.6C). Furthermore, we 
observed that LYVE1 is not exclusively localized in transmembrane position (Fig 6C-
D), but is also present in the extracellular space in proximity of transcytosis vesicles. 
 
Fluorescence micro-lymphangiography on Whole Mount Preparations  
Histological studies are usually restricted to bi-dimensional analysis, limiting the 
possibility to define the three-dimensional pattern of the microvascular network of the 
heart. In order to overcome this limitation, a whole mount micro-lymphangiography 
was performed on the rat skin and heart. After in vivo double labeling by infusion of 
fluorescent tracers (BSA-FITC and TRITC-dextran), whole rat ventricular wall samples 
were first subjected to a clearing procedure and then scanned by confocal microscope. 
This method allows to distinguish double-stained blood vessels (yellow fluorescence) 
from green fluorescent stained lymphatics that are only perfused by BSA-FITC. The 
imaging of whole mount thick samples of the skin clearly define the intricate network of 
blood and lymphatic vessels of this tissue (Fig 7A).  
In the ventricular myocardium, images obtained by fluorescence micro-
lymphangiography confirm the lymphatic location observed by the bi-dimensional 
approach. Most of BSA-FITC fluorescent lymphatic vessels run parallel to blood 
vessels, in the interstitium immediately adjacent to their wall (Fig 7B). Thin lymphatic 
capillaries can be found to a less extent between cardiomyocytes (Fig 7C). 
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CHARACTERIZATION OF LYMPHATIC VASCULATURE IN THE 
PATHOLOGIC RAT HEART 
 
Myocardial infarction 
 To confirm the role of the lymphatic system in heart failure, as reported by 
Ishikawa et al.
37
, in an experimental model we studied the effect of myocardial 
infarction on blood arterioles and on lymphatic vessels. 
 Seven days after coronary occlusion, in the acute remodeling phase, the number 
of SMA
pos
 arterioles in the infarct region results significantly increased. With the 
progression of scar maturation the number of arterioles slowly revert to normal values. 
Indeed, 21 days after induction of MI, when the lesion is replaced by mature scar tissue, 
arteriolar density is not significantly different with respect to normal myocardial (Fig 
8B). At variance with these findings, lymphangiogenesis is not significantly activated 
one week after MI induction. The number of lymphatic vessels begin to rise in the 
infarct region during the last stage of scar formation, with a functionally relevant delay 
respect blood vessels (Fig 8C). 
 These results sustain the hypothesis that lymphatics are involved in fluids 
drainage and removal of inflammatory cells within necrotic tissues. Therefore, the 
lymphatic system, promoting scar maturation, play an essential role in the final 
assessment of myocardial remodeling after MI. 
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Genetically Determined and Pressure Overload Human Cardiac Hypertrophy 
The histologic specimens of human HOCM myectomies stained with Masson’s 
Trichrome exhibited well defined disease features such as myofiber disarray, and 
myocardial fibrosis. Hypertrophic and dismorphic cardiomyocytes appeared to be 
alternated with areas occupied by small size cells. Further analysis of fibrotic tissue 
showed different type of collagen accumulation. Widening of the interstitial space 
between myofibers and perivascular collagen accumulations were clearly detected in 
HOCM myocardium. In addition, a large band of fibrotic scar was present in the 
endocardium. An example of a low power microscopic field of a whole HOCM 
myectomy is documented in Figure 9A. Fibrous septa taking origin from the 
endocardial scar and extending to surround myocardial layers of hypertrophic 
cardiomyocytes were apparent. Thus, the collagen network in the HOCM heart is 
morphologically abnormal and increased in size compared with structurally normal 
hearts. 
In the presence of such histomorphological pattern a strong rarefaction of vascular 
structures was expected, but only immunohistochemical detection of vWF positive 
capillaries showed a statistically relevant reduction in terms of density (number of 
vessel per mm
2
 of analyzed tissue, Fig9C). The lymphatic behavior is totally different. 
The intricate myocardial remodeling observed in HOCM hearts was associated with a 
20 fold increment of lymphatic vessel density in the fibrotic scar (data not shown) and a 
weaker but statistically significant 2,5 fold rise in the myocardium (Fig 9E).  
In HOCM myectomies, immunohistochemical detection of ph-H3 showed high degrees 
of cell proliferation of all myocardial cell populations, including lymphatic endothelial 
cells, of which mitotic index reach 14% and 35% in myocardium and fibrotic scar 
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respectively (Fig 9F).  
Hypertrophic heart specimens obtained from patients with aortic stenosis (AoS) were 
compared to HOCM. Similar increase in capillary and lymphatic vessels were found in 
term of density (Fig 9C-E). However, proliferative indexes of lymphatic endothelial 
cells were more than 20-fold higher in HOCM myocardium with respect to AoS. These 
observations suggest that genetically determined cardiac remodeling in HOCM patients 
is disease specific and characterized by active lymphangiogenesis. 
 
DOXO induced cardiomyopathy 
 The mechanism of toxicity of DOXO is still unclear and there are no evidence 
about the direct involvement of angiogenesis and lymphangiogenesis. In experimental 
rats, treatment with DOXO for two weeks induces dilated cardiomyopathy, heart failure 
and death. The cardiomyopathy is characterized by multiple foci of inflammatory 
damage resulting in scattered focal deposition of collagen. The analysis of lymphatic 
structures conducted in this model of DOXO induced cardiomyopathy shows a 2-fold 
increase in vessel density (Fig 10A). Similar to the observations made in the MI model, 
lymphatic vessel density rises according to collagen deposition and for the 
establishment of myocardial fibrosis.  
 Therefore, in DOXO induced toxic insult on the heart, the lymphatic system also 
promotes replacement of the damaged myocardium by fibrotic tissues.  
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IM induced cardiomyopathy 
As a consequence of three weeks of IM treatment, rats develop a pronounced 
cardiomyopathy. IM impairs cardiac function and produces a restrictive type of LV 
remodeling. Gross structural composition does not significantly change after IM 
treatment; the fractional volume of cardiac muscle is not heavily affected and no 
significant myocardial fibrosis is observed.  
When the ratio of cardiac wet to dry weight is measured, compared to control 
values, an increase of “theoretical” water content in treated hearts is observed, 
especially with 100 mg/kg doses of IM (Fig 10C).  
To evaluate the effect of IM on cardiac lymphatic system, the morphometric 
measurement of lymphatics was assessed by immunofluorescence. The quantitative 
estimation indicates that both 50 mg/kg and 100 mg/kg doses of IM induce a nearly 
70% reduction of lymphatic vasculature (Fig 10B).  
Ultrastructural detection and Immunogold staining of cardiac tissue by TEM 
indicate high levels of damage in lymphatic endothelial cells as a result of IM treatment. 
Significant alterations of subcellular structures were observed both in lymphatic and 
blood vessels of IM treated hearts. In lymphatic endothelial cells we detected specific 
marker of cellular stress, such the presence of swollen and degraded mitochondria and, 
occasionally, cytoplasmic accumulation of degradation products (Fig 10 D-E).  
These data support the hypothesis that lymphatics are involved in normal fluids 
drainage and that the lack of their function may contribute to the development of IM 
related cardiomyopathy. 
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The importance of lymphatic system in the drainage of fluids and toxic 
metabolites in normal and pathological states of the organism is known, but studies of 
lymphatic vessels only lately became histological feasible, due to the recent discovery 
of several lymphatic endothelial cell-specific markers. 
Even if little is known about the role and function of the lymphatic system in the 
heart, the recent identification of lymphatic endothelial cell-specific markers, the 
generation of transgenic “lymphatic-regulated” animal models and advanced lymphatic 
vascular imaging technologies led to a reevaluation of the importance of cardiac 
lymphatic vasculature in the control of heart function. A series of recent promising 
research studies have underlined the effect of active lymph drainage on heart function, 
especially in cardiac pathologies. Evidence that ischemic insults, like MI, can affect the 
lymphatic vasculature indicates its central role in the replacement of damaged 
myocardium by fibrotic tissue 
37
.  
Significant information of our study is provided by the characterization of the 
lymphatic vasculature in mouse, rat, adult and fetal human samples. Notably, several 
methodologies, such as IHC, fluorescence micro-lymphangiography on whole mount 
preparations and TEM analysis were employed to elucidate the role of lymphatics. 
The immunohistochemical analysis allowed us to define the lymphatic 
distribution in myocardial tissues. We consistently observed the location of large 
lymphatic vessels in the epicardial region of the heart, especially in the perivascular 
interstitium. On the other hand, lymphatic capillaries were mostly found in the 
myocardial parenchyma surrounding cardiomyocytes. On the contrary to that reported 
by the literature, we were not able to detect collecting lymphatic vessels surrounded by 
a small layer of smooth muscle cells. A possible explanation of this finding is that the 
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squeezing action produced by cardiomyocyte contraction during the cardiac cycle is 
sufficient to drain fluids and to pump out the lymph from internal lymphatic capillaries 
to collector ducts that are located in the extracardiac region. 
The results of 2D analysis by IHC were confirmed by fluorescence micro-
lymphangiography on whole mount preparations of the heart and skin. The 3D 
reconstruction of lymphatic and blood vasculature allowed us to observe the actual 
morphology and organization of both vascular systems in vivo. By this approach, 
lymphatic vessels were found to run parallel to blood ones, confirming the perivascular 
distribution documented by IHC. In addition, the typical tortuous aspect of lymphatics 
was clearly visible by the 3D confocal reconstruction of the vascular network in the 
skin. Thus, microlymphangiography can be easily applied to understand the 
pathophysiologic implication of cardiac lymphatics in heart failure. 
Finally, TEM combined with Immunogold was used to detect the lymphatic 
vasculature and to analyze the ultrastructural features of lymphatic endothelial cells. In 
the normal heart, TEM identification of lymphatic vessels is facilitated by the evidence 
of typical sub-cellular features, such as fenestration and discontinuation of basal lamina, 
not easily detectable by other methodologies. In addition, Lyve-1 expression highlighted 
by Immunogold gave us further confidence about the real lymphatic nature of the 
observed vessel. Observations obtained in normal hearts by TEM confirmed the pattern 
of lymphatics distribution as shown by IHC and micro-lymphangiography. However in 
IM-induced cardiomyopathy, we observed ultrastructural damages on myocardial 
lymphatic endothelial cells. High incidence of swollen and degraded mitochondria and 
intense accumulation of degradation products in the cytoplasm of lymphatics were 
present. 
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In order to expand our knowledge and to elucidate the role of cardiac 
lymphatics, the lymphatic system in a mouse model of MI, in human myectomies of 
HOCM affected patients and in cardiomyopathies induced by drugs such as DOXO or 
IM were analyzed here. 
Our observations confirm that the lymphatic system, promoting scar maturation, 
plays an essential role in the final assessment of myocardial remodeling after MI.  
In HOCM patients the genetic defined cardiac remodeling observed in our study 
is disease specific and characterized by active lymphangiogenesis. Progressive septal 
tickening and collagen accumulation in HOCM myocardium is supported by a dense 
network of actively proliferating lymphatic vessels. 
Further information earned by our study indicate that the integrity and density of 
lymphatic vessels in DOXO or IM induced cardiomyopathy are differently affected, 
confirming how these structures could be involved in the assessment of different 
pathologic states of the organ. 
DOXO related cardiomyopathy was characterized by changes in lymphatics 
mimicking MI. In this specific cardiomyopathy, lymphatic vessels increase as a result of 
myocardial damage, in order to drain fluid and toxic metabolites from focal area of 
injury and to gradually favour the replacement of necrotic tissue by fibrosis.  
At variance with these results, in IM related cardiomyopathy, myocardial 
lymphatic density is reduced and theoretical water content in treated hearts appears to 
be increased. Both these two phenomena may participate to the pathogenetic mechanism 
of cardiac dysfunction produced by IM and may be inversely related if the principal role 
of cardiac lymphatics in the drainage of fluids is considered. 
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Future perspectives 
Our results suggest an active responsive role of lymphatic system in all the analyzed 
pathological condition, with the exception of IM induced cardiomyopathy. The observed 
tickening of lymphatic web has a “buffer effect” on myocardial microenvironment, 
improving dead cell clearance, waste material drainage and collagen deposition. 
On the other hand, water content increase caused by the strong inhibitory effect of IM 
treatment on myocardial lymphangiogenesis could be a key event in the onset of IM 
induced cardiomyopathy. Myocardial edema is one of the typical feature of human 
myocarditis associated with diastolic dysfunction
75
, conduction disturbances
76
, 
microvascular compression
77
 and tissue swelling.
78
 
It has been clearly documented that c-Kit
pos
 Cardiac Progenitor cells (CPCs) 
play a central role in the control of cardiac homeostasis. Failure of CPC function may 
inevitably lead to a sequence of cellular events culminating in cardiac failure.  
The direct effect of IM on CPCs through the inhibition of c-Kit receptor 
signaling was in part demonstrated by our preliminary studies on treated CPC growth. 
CPC ability to differentiate toward lymphatic phenotype was documented by the 
observation that a small fraction of freshly isolated CPCs cultured in standard 
conditions express the nuclear transcription factor Prox-1, a specific marker of 
lymphatic endothelial cells. Thus, an intrinsic commitment toward lymphatic 
differentiation was confirmed by the increased rate of Prox-1 expression after growing 
CPCs in MV2 conditioned medium. An additional supporting finding was the 
demonstration of a spontaneous tube formation on MATRIGEL
TM
 (BD, New Jersey, 
USA) by CPCs that was comparable with commercial human lymphatic cell line 
(HDLEC). To our knowledge, these data may open new ways for the understanding of 
 
Discussion 
 
 
 
44 
 
the origin of cardiac lymphatic system and its role in physiologic and pathological states 
of the heart. 
Importantly, we show here that TK inhibition by IM exerts a negative effect on 
the ability of CPC to acquire a lymphatic phenotype in the presence of specific 
lymphangiogenic growth factors. Moreover, functional assays were able to document 
that IM hampered tube formation in vitro by CPCs comparable with the commercially 
available HDLEC cell line. A direct interference of TKI on PDGFR pathway is likely to 
be operative in the deleterious effects of IM on lymphatics. PDGF and its receptor 
system are fundamental for the regulation of angiogenesis including 
lymphangiogenesis. In agreement with this contention, however, when the incidence of 
PDGFRpos cells was measured in myocardial tissues, IM treated hearts had a lower 
content of this cell population (data not shown). 
We advanced the hypothesis that CPCs may be involved not only in 
cardiomyogenesis and angiogenesis, but also in cardiac lymphangiogenesis.  
The possibility of preventing cardiomyopathies by modulation of the lymphatic 
system may open new therapeutic options to unravel an unsolved clinical issue. 
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Figure 1. HUMAN LUNG. (A)Immunofluorescence image of a section of the human fetal lung in the 
canalicular phase of lung development stages. (B) Section of human adult lung showing small lymphatics 
in interalveolar areas. (A and B) Endothelial profiles are detected by the red fluorescence of vWF and 
lymphatic vessels by the green fluorescence for Pdpn antibody staining. Pdpn is also detected in the type I 
pneumocytes precursors in the terminal bronchiole (white arrowheads) 
 
Scale bars 100 M  
A 
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Figure 2. HUMAN FETAL HEART. Immunofluorescence image of the subepicardium in human fetal 
hearts. Pdpn expression (green fluorescence) is exclusively detected in lymphatic vessels typically located 
in perivascular spaces around coronary vessels whose lumen is identified by vWF expression (red 
fluorescence). Yellowish fluorescence corresponds to the autofluorescence of red blood cells that are 
present only in the lumen of blood vessels. Scale bar 100 M 
 
 
Figure 3. ADULT HUMAN HEART. Section of the epicardium of an adult human heart documenting 
by immunofluorescence the distinction between endothelial cells lining lymphatic vessels, labelled by 
Pdpn (green fluorescence) and those of a blood vessel (asterisk) labelled by vWF (red fluorescence). Red 
blood cells are recognized by autofluorescence in the lumen of the blood vessel. Large yellowish 
fluorescent spots correspond to phagocytic cells and small orange dots to lipofucsins. Scale bar 100 M 
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Figure 4. HUMAN SKIN. A-D: lymphatics are shown by the green fluorescence of Pdpn and blood 
vessels by vWF (red fluorescence) in the dermal aspect of the human skin. C-D: In association to pdpn, 
lymphatic endothelial cells nuclei express the specific transcription factor Prox-1 (white fluorescence). 
Microscopic images taken in B and D represent higher magnification of A and C, respectively, 
documenting the lack of double immunofluorescence in the same vessel. Scale bar A 250M; C 100M 
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Figure 5. ADULT RAT HEART. A: low magnification of a cross section of the left ventricle (LV) of 
the rat heart as shown after immunofluorescence labelling of cardiomyocytes by a-sarcomeric actin (red 
fluorescence). Areas included in white rectangles are shown at higher magnifications in B and C, 
respectively, and document the typical distribution of lymphatic vessels labelled by Pdpn (green 
fluorescence) in the perivascular interstitium of the epicardium. The expression of the nuclear 
transcription factor Prox-1 (white fluorescence) by nuclei of lymphatic endothelial cells is better 
appreciable in C. D-E: lymphatics are shown by immunofluorescent labelling of the lymphatic marker 
Lyve-1 (green fluorescence) whereas arteries by a-smooth muscle actin (red fluorecence). Small 
lymphatic profiles can also lie in the interstitium between cardiomyocytes (E).                                     
Scale bar A 1mm; B 50 M; D 100M; E 25 M 
A C B 
D E 
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Figure 6. ULTRASTRUCTURAL AND IMMUNOGOLD DETECTION OF LYMPHATICS IN 
THE NORMAL RAT HEART. A: a lymphatic vessel located between cardiomyocytes (CM). A 
characteristic fenestrations of the endothelial cell layer is shown in figure B. C-D: immunogold using the 
specific lymphatic marker Lyve-1. Immunoreactivity for Lyve-1 is shown by small dark round dots 
(arrowheads) mostly located along the cytoplasmic extensions of lymphatic endothelial cells and in 
transmembrane position. 
* lymphatic lumen 
 
CM 
CM 
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Figure 7. FLUORESCENCE MICRO-LYMPHANGIOGRAPHY ON WHOLE MOUNT 
PREPARATIONS OF THE RAT HEART AND SKIN. A: section of the rat skin showing by 
yellowish fluorescence a large (diameter approximately 100 mm) blood vessel and its branching as 
defined by the double fluorescence of FITC-BSA and TRITC-Dextran. Two lymphatics showing the 
typical irregular profile are recognized by the green fluorescence due to the selective perfusion by FITC-
BSA. B and C: 3D reconstruction of the microcirculation in two sections of the left ventricle of an adult 
rat heart. Blood vessels (yellow fluorescence) show both injected dyes whereas lymphatics are perfused 
only by BSA-FITC tracer (green fluorescence). A large coronary vessel appears predominantly, although 
not uniquely, perfused by Dextran. Most larger lymphatics run parallel to blood vessels (B) and some 
lymphatic capillaries are detectable between cardiomyocytes (C). Scale bar : 100 M  
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Figure 8. EFFECT OF MYOCARDIAL INFARCTION ON VASCULAR STRUCTURES. A: image 
of vascular components in the infarcted rat heart by immunofluorescence. Lymphatic vessels are detected 
by Lyve-1 (green fluorescence), whereas arterioles by specific anti -SMA antibody (red fluorescence).B 
and C: bar graphs showing arteriolar and lymphatic density one week and 21 days after MI. Only 
arteriolar density significantly increases at 7 days, while lymphatic vessels are unchanged. After three 
weeks, corresponding to the completion of scar, lymphatic density results 6-fold higher than control while 
arteriolar density decrease to control (CTRL) values. Scale bar  50 M 
* p<0.05vs CTRL 
** p<0.05vs 7 days 
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Figure 9. EFFECT OF HOCM VASCULAR STRUCTURES. A: Low power view of a section of the 
entire myectomy obtained from a HOCM patient and stained with Masson’s Trichrome. The fibrotic 
tissue (bluish) involves a thick endocardial area from which collagen bundles seems to branch in 
interstitial septa separating myofibers (reddish). B and C: Immunohistochemical detection of vWF 
positive capillaries (red staining in B) showed a statistically relevant reduction in terms of density in both 
hypertrophic groups. D: Proliferating lymphatic vessels are detected by double staining of Pdpn (red 
fluorescence) and PhH3 (green fluorescence) E: Lymphatic vessel density showed a statistically 
significant 2,5 fold rise in the myocardium of HOCM and AoS. F: Mitotic Index of Cardiac lymphatics. 
In AoS the percentage of doubling lymphatic endothelial cells remain under 1% without significant 
differences respect control myocardium. In HOCM myectomies lymphatic mitotic index reach 14% and 
35% in myocardium and fibrotic scar respectively. Scale Bars: B 50m; D 25m 
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Figure 10. EFFECT OF DOXO AND IM TREATMENTS ON LYMPHATIC VESSELS OF THE 
RAT HEART. A: DOXO-induced cardiomyopathy is characterized by increased lymphatic density. B: 
IM- induced cardiomyopathic heart shows a significant reduction of lymphatic vessels coupled with an 
increased “theoretical” water content (C). D and E: TEM images documenting the presence of swollen 
and degrated mitochondria (D) and cytoplasmic accumulation of degradation products (E) in the 
lymphatic endothelial cells. 
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